Teva To Pay $270M In Propofol Hepatitis Suits

By Erin Fuchs · February 21, 2012, 4:07 PM EST

Teva Pharmaceuticals Industries Ltd. will spend roughly $270 million on suits claiming the way it packaged its anesthetic Propofol caused a hepatitis C outbreak, Teva told securities regulators Friday, revealing it...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Erin

April 16, 2012
Big Tobacco Cos. Challenge $6.5B Payout Deal With States
April 10, 2012
Minn. Gov. Nixes Bill Curbing Cos.' Asbestos Liability
March 22, 2012
Judge Trims Expert Testimony In Novartis Bone Drug Suit
March 08, 2012
Tobacco Ads Spurred Minors To Smoke, Surgeon General Says
March 02, 2012
Merck Action Didn't Stop The Clock, Va. High Court Says
February 28, 2012
Merck Failed To Probe Diabetes Drugs For Risks: FDA
February 24, 2012
Nixon Peabody Lands Ex-Pillsbury Gov't Contracts Pro
February 23, 2012
Texas Drug Fraud Law Preempted In J&J Suit: 5th Circ.
February 21, 2012
High Court Nixes Nursing Home Death Arbitration Ruling
February 16, 2012
WTC Panel To Back Cancer Coverage For 9/11 Victims: CDC